BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ocifisertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ocifisertib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03624543-2914@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Ocifisertib: Phase 2 readout est. (NCT03624543)
DESCRIPTION:Ocifisertib\, phase 2.\nStudy: CFI-400945 in Patients With Adva
 nced/Metastatic Breast Cancer\nEstimated primary completion: 30 November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ocifisertib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03624543
URL:https://assetmemo.bio/drug/ocifisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05601440-2914@assetmemo.bio
DTSTAMP:20261121T005605Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocifisertib: Phase 2 readout est. (NCT05601440)
DESCRIPTION:Ocifisertib\, phase 2.\nStudy: Liquid-biopsy Informed Platform 
 Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast C
 ancer\nEstimated primary completion: 31 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ocifisertib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05601440
URL:https://assetmemo.bio/drug/ocifisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
